|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 鳞状上皮细胞癌抗原水平新检测方法在宫颈癌、肺癌和头颈部癌鉴别诊断中的性能及临床表现显示文摘鳞状上皮细胞癌抗原水平在鳞状上皮细胞癌中通常升高。这项多中心研究评估了一种新的Elecsys?鳞状上皮细胞癌检测的检测性能,该检测方法是以等摩尔方式测量血清鳞状上皮细胞癌抗原1和2的水平,并研究了鳞状上皮细胞癌抗原用于宫颈癌、肺癌和头颈部鳞状上皮细胞癌鉴别诊断的潜能。在欧洲三个研究中心进行了精确度和方法学比较实验。健康人群的参考区间使用来自欧洲和中国人群的样本确定的。鉴别诊断试验确定了鳞状上皮细胞癌抗原水平能否将宫颈癌、肺癌或头颈癌与表观健康的、良性的或其他恶性群组区分开来。根据95%特异性下的鳞状上皮细胞癌抗原水平计算出鳞状上皮细胞癌抗原医学截断值。9个分析浓度的重复性变异系数<5.3%,中间精密变异系数<0.3%。方法学比较显示,与Architect和Kryptor系统具有很好的相关性(斜率分别为1.1和1.5)。表观健康人群的第95百分位数的参考区间为2.3 ng/m L(95%置信区间:1.9-3.8;欧洲队列,n=153)和2.7 ng/m L(95%置信区间:2.2-3.3;中国队列,n=146)。最佳的鉴别诊断结果见于宫颈鳞状上皮细胞癌:受试者工作特征曲线分析显示鳞状上皮细胞癌抗原水平(2.9 ng/m L的医学截断值)鉴别宫颈鳞状上皮细胞癌(n=127)与表观健康女性(n=286;曲线下面积:86.2%;95%置信区间:81.8-90.6;灵敏度:61.4%;特异性:95.6%),良性疾病(n=187;曲线下面积:86.3%;95%置信区间:81.2-91.3;灵敏度:61.4%;特异性:95.0%)和其他宫颈癌(n=157;曲线下面积:78.9%;95%置信区间:70.8-87.1;灵敏度:61.4%;特异性:86.7%)。鳞状上皮细胞癌还可帮助鉴别诊断肺癌。Elecsys鳞状上皮细胞癌检测技术在宫颈鳞状上皮细胞癌的临床实践中表现出了良好的性能,适合用于鉴别诊断。 | Stefan HOLDENRIEDER Rafael MOLINA Ling QIU Xiuyi ZHI Sandra RUTZ Christine ENGEL Pia KASPER- SAUER Farshid DAYYANI Catharina Mkorse | 2018 | 中国肺癌杂志2018，21，7： | 13 |
| 2 | 一项在欧洲和中国进行的新型胃泌素释放肽前体(ProGRP)免疫检测多中心评估研究显示文摘背景在欧洲和中国进行Elecsys?胃泌素释放肽前体(ProGRP)免疫检测的多中心评估研究。方法在欧洲的3个中心和中国的2个中心,在肺癌中,通过不精密度、稳定性、方法学比较和鉴别诊断能力来评价该检测法。结果 5个分析物浓度的中间不精密度范围为变异系数:2.2%-6.0%。在不同储存条件下,血浆和血清样本均显示出良好的稳定性。在血浆中Elecsys?和ARCHITECT检测(斜率1.02,截距-2.72 pg/m L)之间表现出良好的相关性。同时,Elecsys?检测在血清和血浆样本之间表现出良好的相关性(斜率0.93,截距2.35 pg/m L;相关系数0.97)。ProGRP作为不受种族、年龄、性别或吸烟史相关影响的检测手段,可鉴别小细胞和非小细胞肺癌(NSCLC);截断值为84pg/m L时,曲线下面积为0.90,95%CI:0.87-0.93;敏感性为78.3%,特异性为95%。ProGRP浓度中位数在良性病变(38pg/m L)、其他恶性肿瘤(40 pg/m L)或NSCLC(39 pg/m L)中较低,而在3期以上慢性肾脏疾病中浓度较高(>100pg/m L)。结论 Elecsys?ProGRP检测在血清和血浆中稳定性增加,较现有检测法明显更具优势。ProGRP检测在中国的首次评价在不同种族中显示出相当的鉴别能力。 | Catharina M.KORSE Stefan HOLDENRIEDER Xiuyi ZHI Xiaotong ZAHNG Ling QIU Andrea GEISTANGER Marcus-Rene LISY Birgit WEHNL Daan van den BROEK José M.ESCUDERO Jens STANDOP Mu HU Rafael MOLINA | 2017 | 中国肺癌杂志2017，20，8： | 7 |
| 3 | Immune checkpoint therapy for pancreatic cancer显示文摘Novel treatment modalities are necessary for pancreatic cancer. Immunotherapy with immune checkpoint inhibition has shown effect in other solid tumors, and could have a place in pancreatic cancer treatment. Most available clinical studies on immune checkpoint inhibitors for pancreatic cancer are not yet completed and are still recruiting patients. Among the completed trials, there have been findings of a preliminary nature such as delayed disease progression and enhanced overall survival after treatment with immune checkpoint inhibitors in mono- or combination therapy. However, due to small sample sizes, major results are not yet identifiable. The present article provides a clinical overview of immune checkpoint inhibition in pancreatic cancer. Pub Med, Clinical Trials.gov and American Society of Clinical Oncology's meeting abstracts were systematically searched for relevant clinical studies. Four articles, five abstracts and 25 clinical trials were identified and analyzed in detail. | Henrik Johansson Roland Andersson Monika Bauden Sarah Hammes Stefan Holdenrieder Daniel Ansari | 2016 | World Journal of Gastroenterology2016，22，43： | 4 |
| 4 | Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy显示文摘 | Michael Haas Volker Heinemann Frank Kullmann Rüdiger P. Laubender Christina Klose Christiane J. Bruns Stefan Holdenrieder Dominik P. Modest Christoph Schulz Stefan Boeck | 2013 | Journal of Cancer Research and Clinical Oncology2013，，4： | 4 |
| 5 | Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer显示文摘 | Ugur Gezer Duran üstek Ebru E. Y?rüker Aris Cakiris Neslihan Abaci Gloria Leszinski Nejat Dalay Stefan Holdenrieder | 2013 | Tumor Biology2013，，1： | 2 |
| 6 | Circulating nueleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer显示文摘 | Holdenrieder S Stieber P von Pawel J | 2004 | Clin Cancer Res2004，10，181： | 1 |
| 7 | Nucleosomes in serum of patients with early cerebral stroke 显示文摘 | Geiger S Holdenrieder S Stieber P | 2006 | Cerebrovasc Dis2006，21，12： | 1 |
| 8 | Clinical relevance of thymidine kinase for the diagnosis,therapy monitoring and prognosis of non-operable lung cancer显示文摘 | Holdenrieder S Von Pawel J Duell T | 2010 | Anticancer Research2010，30，5： | 1 |
| 9 | Nucleosomes, ProGRP, NSE, CYFRA 21 -1, and CEA in monitoring first-line chemotherapy of small cell lung cancer显示文摘 | Holdenrieder S von Pawel J Dankelmann E | 2008 | Clin Cancer Res2008，14，23： | 1 |
| 10 | Nucleosomes in serum as a marker for cell death显示文摘 | Holdenrieder S Stieber P Bodenmüller H | 2001 | Clinical Chemistry and Laboratory Medicine2001，39，7： | 1 |
| 11 | Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer 显示文摘 | Boeck S Stieber P Holdenrieder S | 2006 | Oncology2006，70，4： | 1 |
| 12 | Nucleosomal DNA fragments in autoimmune diseases显示文摘 | Holdenrieder S Eichhorn P Beuers U | 2006 | Ann N Y Acad Sci2006，1075，： | 1 |
| 13 | Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer显示文摘 | Boeck S Stieber P Holdenrieder S | 2006 | Oncology2006，70，4： | 1 |
| 14 | Soluble MICA in malignant diseases显示文摘 | Holdenrieder S Stieber P Peterfi A | 2006 | Int Cancer2006，118，3： | 1 |
| 15 | Apoptosis in serum of patients with solid tumours显示文摘 | Holdenrieder S Stieber P Forg T | 1999 | Anticancer Res1999，19，4： | 1 |
| 16 | Nucleosomes andCYFRA21-1 indicate tumor response after one cycle of chemotherapyinrecurrent non-small cell lung cancer 显示文摘 | Holdenrieder S VonPawel J Dankelmann E | 2009 | Lung Cancer2009，63，1： | 1 |
| 17 | Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cetl lung cancer显示文摘 | Holdenrieder S yon Pawel J Dankelmann E | 2008 | Clin Cancer Res2008，14，23： | 1 |
| 18 | Nucleosomes, ProGRP, NSE,CYFRA-211,and CEA in monitoring first linechemotherapy of small cell lung cancer显示文摘 | Holdenrieder S von Pawel J Dankelmann E | 2008 | Clin Cancer Res2008，14，23： | 1 |
| 19 | Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer 显示文摘 | Boeck S Stieber P Holdenrieder S | 2006 | Oncology2006，70，4： | 1 |
| 20 | Nucleosomes in serum as a marker for cell death显示文摘 | Holdenrieder S Stieber P Bodenmuller H | 2001 | Clin Chem Lab Med2001，39，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员